RU2696892C2 - САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII - Google Patents

САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII Download PDF

Info

Publication number
RU2696892C2
RU2696892C2 RU2016106577A RU2016106577A RU2696892C2 RU 2696892 C2 RU2696892 C2 RU 2696892C2 RU 2016106577 A RU2016106577 A RU 2016106577A RU 2016106577 A RU2016106577 A RU 2016106577A RU 2696892 C2 RU2696892 C2 RU 2696892C2
Authority
RU
Russia
Prior art keywords
egfrviii
seq
binding
binding protein
cells
Prior art date
Application number
RU2016106577A
Other languages
English (en)
Russian (ru)
Other versions
RU2016106577A (ru
Inventor
Кристина ЭЛЛВАНГЕР
Уве РОЙШ
Ивица ФУЦЕК
Стефан КНАКМУС
Вера МОЛКЕНТИН
Мелвин ЛИТЛ
Евгений ЖУКОВСКИ
Original Assignee
Аффимед Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аффимед Гмбх filed Critical Аффимед Гмбх
Publication of RU2016106577A publication Critical patent/RU2016106577A/ru
Application granted granted Critical
Publication of RU2696892C2 publication Critical patent/RU2696892C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2016106577A 2013-08-07 2014-08-07 САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII RU2696892C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13179630 2013-08-07
EP13179630.2 2013-08-07
EP13189599.7 2013-10-21
EP13189599 2013-10-21
PCT/EP2014/002177 WO2015018527A1 (en) 2013-08-07 2014-08-07 ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII

Publications (2)

Publication Number Publication Date
RU2016106577A RU2016106577A (ru) 2017-09-14
RU2696892C2 true RU2696892C2 (ru) 2019-08-07

Family

ID=51453717

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016106577A RU2696892C2 (ru) 2013-08-07 2014-08-07 САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII

Country Status (13)

Country Link
US (1) US10273309B2 (https=)
EP (1) EP3030581B1 (https=)
JP (1) JP6529498B2 (https=)
CN (1) CN105555804B (https=)
AU (1) AU2014304930B2 (https=)
CA (1) CA2920173C (https=)
DK (1) DK3030581T3 (https=)
HR (1) HRP20210561T1 (https=)
HU (1) HUE054057T2 (https=)
LT (1) LT3030581T (https=)
RU (1) RU2696892C2 (https=)
SI (1) SI3030581T1 (https=)
WO (1) WO2015018527A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6632984B2 (ja) * 2014-03-11 2020-01-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ＥＧＦＲｖＩＩＩ抗体およびその使用
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
EP2982693A1 (en) 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
DK3239177T3 (da) * 2014-11-25 2021-04-26 Pharmabcine Inc Nyt egfrviii antistof og sammensætning omfattende samme
US10738118B2 (en) 2015-05-29 2020-08-11 Amphivena Therapeutics, Inc. Methods of using bispecific CD33 and CD3 binding proteins
AU2016274767B2 (en) * 2015-06-09 2022-05-19 Eureka Therapeutics, Inc. T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA
EP3916018A1 (en) * 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) * 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
CN109219618B (zh) 2016-01-21 2022-08-09 辉瑞大药厂 针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
TWI755547B (zh) 2016-01-21 2022-02-21 美商輝瑞股份有限公司 靶向表皮生長因子受體變異體iii之嵌合型抗原受體
EA201891753A1 (ru) 2016-02-03 2019-01-31 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
CN107556386A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗EGFRvIII和CD3特异性双靶向抗体、含双靶向抗体表达盒的微环DNA及应用
AU2017306506B2 (en) 2016-08-05 2020-05-21 Y-Biologics Inc. Antibody to programmed cell death 1 (PD-1) and use thereof
RU2721582C1 (ru) 2016-08-05 2020-05-20 И-Байолоджикс Инк. Антитела против лиганда-1 запрограммированной смерти (PD-L1) и их применение
CN106501518A (zh) * 2017-01-06 2017-03-15 北京弘润天源生物技术股份有限公司 一种检测EGFRvⅢ的免疫组化抗体试剂及检测方法
WO2018158349A1 (en) * 2017-02-28 2018-09-07 Affimed Gmbh Tandem diabody for cd16a-directed nk-cell engagement
IL325995A (en) 2018-02-08 2026-03-01 Genentech Inc Bispecific antigen binding molecules and methods of use
BR112020018492A2 (pt) * 2018-03-14 2020-12-29 Affimed Gmbh Proteína de ligação ao antígeno egfr/cd16 biespecífica
CR20210330A (es) * 2018-12-21 2021-07-20 Hoffmann La Roche ANTICUERPOS QUE SE UNEN A CD3 (Divisional 2021-0325)
US20230192805A1 (en) * 2019-01-14 2023-06-22 Nanjing Legend Biotech Co., Ltd. Chimeric receptor polypeptides and uses thereof
WO2021119505A1 (en) 2019-12-13 2021-06-17 Genentech, Inc. Anti-ly6g6d antibodies and methods of use
JP7620780B2 (ja) * 2020-06-30 2025-01-24 ノナ・バイオサイエンシーズ・（シャンハイ）・カンパニー・リミテッド Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質
WO2022159685A2 (en) * 2021-01-22 2022-07-28 Vanderbilt University Sars-cov-2 coronavirus antibodies and uses thereof
EP4337330A1 (en) 2021-05-14 2024-03-20 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
WO2023287941A2 (en) * 2021-07-16 2023-01-19 Medical Guidance Systems, Llc Anti-tax interacting protein-1 (tip1) binding molecules
CN116375868A (zh) * 2021-12-31 2023-07-04 康源博创生物科技(北京)有限公司 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用
EP4724490A2 (en) 2023-06-12 2026-04-15 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2317999C2 (ru) * 2000-02-25 2008-02-27 Те Гавернмент Оф Те Юнайтед Стейтс, Эз Репризентед Бай Те Секретари Оф Те Департмент Оф Хелт Энд Хьюман Сервисез SCFV ПРОТИВ EGFRvIII С УЛУЧШЕННОЙ ЦИТОТОКСИЧНОСТЬЮ И ВЫХОДОМ, ИММУНОТОКСИНЫ НА ИХ ОСНОВЕ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP2457586A1 (en) * 2003-06-27 2012-05-30 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19819846B4 (de) * 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2317999C2 (ru) * 2000-02-25 2008-02-27 Те Гавернмент Оф Те Юнайтед Стейтс, Эз Репризентед Бай Те Секретари Оф Те Департмент Оф Хелт Энд Хьюман Сервисез SCFV ПРОТИВ EGFRvIII С УЛУЧШЕННОЙ ЦИТОТОКСИЧНОСТЬЮ И ВЫХОДОМ, ИММУНОТОКСИНЫ НА ИХ ОСНОВЕ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP2457586A1 (en) * 2003-06-27 2012-05-30 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHOI B.D. et al., Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma, PNAS, 2013, vol. 110, no. 1, p.270-275. *

Also Published As

Publication number Publication date
WO2015018527A1 (en) 2015-02-12
CA2920173A1 (en) 2015-02-12
JP2016536322A (ja) 2016-11-24
US10273309B2 (en) 2019-04-30
EP3030581B1 (en) 2021-01-20
HUE054057T2 (hu) 2021-08-30
BR112016002610A8 (pt) 2018-01-23
US20160152728A1 (en) 2016-06-02
DK3030581T3 (da) 2021-04-12
CN105555804A (zh) 2016-05-04
HK1218552A1 (zh) 2017-02-24
EP3030581A1 (en) 2016-06-15
LT3030581T (lt) 2021-05-25
HRP20210561T1 (hr) 2021-05-14
AU2014304930A1 (en) 2016-02-25
RU2016106577A (ru) 2017-09-14
JP6529498B2 (ja) 2019-06-12
BR112016002610A2 (pt) 2017-09-12
CN105555804B (zh) 2020-12-25
SI3030581T1 (sl) 2021-07-30
AU2014304930B2 (en) 2019-11-21
CA2920173C (en) 2021-08-10

Similar Documents

Publication Publication Date Title
RU2696892C2 (ru) САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII
JP7411316B2 (ja) 三重特異性結合タンパク質と使用方法
US12202911B2 (en) Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
JP6907124B2 (ja) Ｃｄｈ３及びｃｄ３に対する二重特異性抗体構築物
EP3470426A1 (en) Multispecific antibody
KR20200104305A (ko) 삼중 사슬 항체(Triple-Chain Antibody)의 제조 방법 및 용도
US20240392003A1 (en) Multispecific antibodies having specificity for ror1 and cd3
US20230192861A1 (en) Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
TW201920282A (zh) 抗egfr和pd-1的雙特異性抗體
JP2023526977A (ja) Ｃｄ４０結合タンパク質
KR20230154235A (ko) NKp46에 대한 항체 및 이의 적용
JP2022530496A (ja) Ｐｄ－１およびｌａｇ－３に対する二重特異性抗体
JP2024516748A (ja) ＥＧＦＲｖＩＩＩ結合タンパク質
TWI835166B (zh) 靶向pd-1和/或ox40的特異性結合蛋白及其應用
EP4574844A1 (en) Multispecific antibodies having specificity for cd47 and pdl1
WO2025113640A1 (zh) 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途
WO2025040144A1 (zh) B7-h7抗原结合分子及其应用
HK1218552B (zh) 对egfrviii有特异性的抗体结合位点
WO2024165049A1 (zh) 抗cdh6的抗体及其用途
BR112016002610B1 (pt) Anticorpo de ligação a locais específicos para egfrviii
NZ744187B2 (en) Therapeutic anti-cd9 antibody